In the past few years, substantial preclinical and experimental advances have been made in the treatment of the severe monogenic skin blistering disease epidermolysis bullosa (EB). Promising approaches have been developed in the fields of protein and cell therapies, including allogeneic stem cell transplantation; in addition, the application of gene therapy approaches has become reality. The first ex vivo gene therapy for a junctional EB (JEB) patient was performed in Italy more than 8 years ago and was shown to be effective. We have now continued this approach for an Austrian JEB patient. Further, clinical trials for a gene therapy treatment of recessive dystrophic EB are currently under way in the United States and in Europe. In this review, we aim to point out that sustainable correction of autologous keratinocytes by stable genomic integration of a therapeutic gene represents a realistic option for patients with EB.

Advances in Gene/Cell Therapy in Epidermolysis Bullosa / Murauer, Eva M; Koller, Ulrich; Pellegrini, Graziella; DE LUCA, Michele; Bauer, Johann W.. - In: KEIO JOURNAL OF MEDICINE. - ISSN 0022-9717. - ELETTRONICO. - 64:2(2015), pp. 21-25. [10.2302/kjm.2014-0013-RE]

Advances in Gene/Cell Therapy in Epidermolysis Bullosa

PELLEGRINI, Graziella;DE LUCA, Michele;
2015

Abstract

In the past few years, substantial preclinical and experimental advances have been made in the treatment of the severe monogenic skin blistering disease epidermolysis bullosa (EB). Promising approaches have been developed in the fields of protein and cell therapies, including allogeneic stem cell transplantation; in addition, the application of gene therapy approaches has become reality. The first ex vivo gene therapy for a junctional EB (JEB) patient was performed in Italy more than 8 years ago and was shown to be effective. We have now continued this approach for an Austrian JEB patient. Further, clinical trials for a gene therapy treatment of recessive dystrophic EB are currently under way in the United States and in Europe. In this review, we aim to point out that sustainable correction of autologous keratinocytes by stable genomic integration of a therapeutic gene represents a realistic option for patients with EB.
2015
6-giu-2015
64
2
21
25
Advances in Gene/Cell Therapy in Epidermolysis Bullosa / Murauer, Eva M; Koller, Ulrich; Pellegrini, Graziella; DE LUCA, Michele; Bauer, Johann W.. - In: KEIO JOURNAL OF MEDICINE. - ISSN 0022-9717. - ELETTRONICO. - 64:2(2015), pp. 21-25. [10.2302/kjm.2014-0013-RE]
Murauer, Eva M; Koller, Ulrich; Pellegrini, Graziella; DE LUCA, Michele; Bauer, Johann W.
File in questo prodotto:
File Dimensione Formato  
64_2014-0013-RE.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 984.28 kB
Formato Adobe PDF
984.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1069791
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? ND
social impact